What is PTGX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 9.30B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for PTGX?

P/E (TTM) is 112.18 and 52-week range is $65.56 to $160.81 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s PTGX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for PTGX?

The company profile lists revenue (TTM) near $255M, net income (TTM) near $75M, EPS (TTM) near $1.04 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Protagonist Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Newark California, California, US, 64.3M shares outstanding, ISIN US74366E1029 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Protagonist Therapeutics Inc

$PTGX

Health Care · Biotechnology

IR Run Scenarios

$143.73

+2.73%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. The company is headquartered in Newark California, California and currently employs 132 full-time employees. The company went IPO on 2016-08-11. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its two peptides derived from its proprietary discovery technology platform, rusfertide and icotrokinra, are in advanced Phase III clinical development. Its rusfertide (PTG-300) is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. Icotrokinra, an orally delivered IL-23R specific antagonist for the potential treatment of psoriasis, psoriatic arthritis (PsA), ulcerative colitis and inflammatory bowel disease (IBD) indications. The firm also has a pre-clinical stage oral drug discovery program addressing clinically and commercially validated targets, including the IL-17 oral peptide antagonist PN-881, an oral hepcidin program, and an oral obesity program.

Employees

131

Website

www.protagonist-inc.com/

IPO

2016-08-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)